Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
NB Private Equity Partners
2025 CMD: good returns from low-risk PE model
3rd Dec 2025
Real Estate Credit Investments (RECI)
Investor Day: opportunities aplenty
2nd Dec 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
125: EIS and VC Basics: How venture capital exits work in EIS & VCTs | Kealan Doyle of Symvan Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Register now for Wednesday 21 January 2026 at 12:30pm -
Event | Four distinct approaches to EIS investing: Tax Advantaged Online Forum
Life Sciences research
Advanced Oncotherapy
Life Sciences
Preparing for commercialisation
By
Dr Martin Hall
16 Apr 2019
ValiRx
Life Sciences
VAL401 is going forward
By
Dr Martin Hall
15 Apr 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Tissue Regenix
Life Sciences
Expanded GPO coverage secured
By
Dr Martin Hall
10 Apr 2019
Life Sciences
Global Pharmaceuticals: 2018 industry statistics
By
Dr Martin Hall
09 Apr 2019
genedrive Plc
Life Sciences
First commercial sales in new focus area: bio-threats
08 Apr 2019
Oxford BioMedica
Life Sciences
Deal-making drives first annual profit
02 Apr 2019
Allergy Therapeutics plc
Life Sciences
Take an objective view
18 Mar 2019
Allergy Therapeutics plc
Life Sciences
Strong operating performance driving market share
06 Mar 2019
Collagen Solutions Plc
Life Sciences
Exciting growth
By
Dr Martin Hall
22 Feb 2019
Yourgene Health
Life Sciences
EBITDA-positive in fiscal 2020
22 Feb 2019
Yourgene Health
Life Sciences
Transformed and de-risked
19 Feb 2019
Prev
1
...
9
10
11
12
13
...
22
Next
